Biotech | January 22, 2022
Pfizer and OPKO update on the Biologics License Application for Somatrogon
Pfizer is evaluating the FDA’s comments and will work with the agency to determine an appropriate path forward
Pfizer is evaluating the FDA’s comments and will work with the agency to determine an appropriate path forward
The company will receive an upfront payment as well as regulatory and sales based milestone payments from Lotus
Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach
This agreement allows Natco to expand access to Covid-19 medicines in 105 countries in generic name
They will commercialize molnupiravir in the international markets
This is the company’s first partnership arrangement in China
The artificial cornea is 100% made of non-biological materials and require no co-implantation of donor corneas and it is an ideal option for treating patients with corneal blindness
Industry Report highlights the opportunities and need for multiple sectoral collaboration through 12 actionable recommendations under 6 thematic areas
The acquisition would enable addition of established brands with high recall amongst healthcare professionals, especially in the vitamins, minerals and supplements category
The company has 47 ANDA's pending approval with the U.S.FDA
Subscribe To Our Newsletter & Stay Updated
